CCRM
Deepika Sidhu is a Quality Control Microbiologist at Bimeda since March 2021, where responsibilities include leading investigations related to microbial data deviations and developing and validating testing methods for raw materials and final products. Prior to this role, Deepika served as the Lead Document Compiler and Lead Biotechnologist at Labstat International ULC from March 2016 to March 2021, focusing on GLP studies and conducting mutagenicity and cytotoxicity studies on nicotine-containing products. Deepika holds an M.Sc. in Microbiology and Immunology from the Central Research Institute in Kasauli, India, and a B.Sc. in Microbiology from Punjab University, India, along with studies at Seneca Polytechnic from 2013 to 2015.
This person is not in any teams
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.